Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
CN¥49.00 - CN¥109.89
Next Earnings Date
-
Next Earnings Date
-
Latest price
Market Cap | CN¥27.20B |
EV | CN¥26.07B |
Shares Outstanding | 264.71M |
Beta | 0.47 |
Analyst Rating | BUY |
Analyst Target Price | CN¥135.00 |
P/E 2025E | 294.22x |
P/Revenue 2025E | 32.22x |
Revenue | 38.50% |
EPS | 33.50% |
Operating Cash Flow | - |
Free Cash Flow | 52.20% |
Revenue | 59.40% |
EPS | - |
Operating Cash Flow | 103.60% |
Free Cash Flow | - |
Gross Margin 2025E | 92.22% |
Net Profit Margin 2025E | -3.68% |
ROE 2025E | -2.57% |
ROCE 2024 | -9.55% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.
688266
Sector
Healthcare
Industry
Biotechnology
CEO
Sheng, Zelin
Employees
867
Website
www.zelgen.comIPO Date
2020-01-23
Headquarters
No. 209, Chenfeng Road, Kunshan, Jiangsu Province, 215300, China
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved